High intestinal and systemic levels of interleukin-23/T-helper 17 pathway in Chinese patients with inflammatory bowel disease.
High intestinal and systemic levels of interleukin-23/T-helper 17 pathway in Chinese patients with inflammatory bowel disease.
复制标题
中国炎症性肠病患者肠道和全身高水平的 IL-23/T-Helper 17 通路
DOI：
10.1155/2013/425915
复制
发表时间：
2013
影响因子：
4.6
通讯作者：
Xia B
中科院分区：
文献类型：
--
作者：
Song L;Zhou R;Huang S;Zhou F;Xu S;Wang W;Yi F;Wang X;Xia B
白细胞介素-23/辅助性t - 17 （IL-23/Th17）通路在炎症性肠病（IBD）发病机制中起关键作用，但其在中国人群中的表达情况尚不清楚。在这项研究中，我们研究了中国IBD患者局部和全身IL-12p40、肿瘤坏死因子样细胞因子1A （TL1A）、Janus激酶2 （JAK2）和IL-23R的mRNA和蛋白水平。我们的研究结果表明，溃疡性结肠炎（UC）患者IL-12p40和TL1A mRNA水平升高。此外，活动性UC患者的血清IL-12p40和TL1A水平较高，特别是病程少于1.25年或首次发病的患者。UC患者IL-12p40或TL1A基因型与血清水平无相关性。此外，UC和克罗恩病（CD）患者中JAK2和IL-23R的mRNA和蛋白表达均升高。综上所述，我们的研究结果证明IL-23/Th17通路基因可能是IBD活跃期的重要生物标志物，并可作为中国人群IBD新的治疗靶点。
Interleukin-23/T-helper 17 (IL-23/Th17) pathway plays a key role in the pathogenesis of inflammatory bowel disease (IBD), but little is known about its expression in Chinese population. In this study, we investigated the mRNA and protein levels of IL-12p40, tumor necrosis factor-like cytokine 1A (TL1A), Janus kinase 2 (JAK2), and IL-23R both locally and systemically in Chinese IBD patients. Our results indicated that the mRNA levels of IL-12p40 and TL1A were increased in ulcerative colitis (UC) patients. Furthermore, serum IL-12p40 and TL1A levels were higher in active UC patients, especially in patients with disease course less than 1.25 years or initial onset. No correlation was found between the genotype and serum levels of IL-12p40 or TL1A in UC patients. Additionally, the mRNA and protein expression of JAK2 and IL-23R were increased in UC and Crohn's disease (CD) patients. Taken together, our results provided evidence that IL-23/Th17 pathway genes may represent important biomarkers of active stage of IBD and serve as novel therapeutic targets for IBD in Chinese population.
登录
查看更多内容
影响因子：
30.8
作者：
通讯作者：
--
溃疡性结肠炎中克罗恩病风险的研究进一步定义了它们的分子关系。
影响因子：
29.4
作者：
Anderson CA;Massey DC;Barrett JC;Prescott NJ;Tremelling M;Fisher SA;Gwilliam R;Jacob J;Nimmo ER;Drummond H;Lees CW;Onnie CM;Hanson C;Blaszczyk K;Ravindrarajah R;Hunt S;Varma D;Hammond N;Lewis G;Attlesey H;Watkins N;Ouwehand W;Strachan D;McArdle W;Lewis CM;Wellcome Trust Case Control Consortium;Lobo A;Sanderson J;Jewell DP;Deloukas P;Mansfield JC;Mathew CG;Satsangi J;Parkes M
通讯作者：
Parkes M
DOI：
10.1084/jem.20061775
发表时间：
2006-11-27
期刊：
The Journal of experimental medicine
影响因子：
--
作者：
Sato K;Suematsu A;Okamoto K;Yamaguchi A;Morishita Y;Kadono Y;Tanaka S;Kodama T;Akira S;Iwakura Y;Cua DJ;Takayanagi H
通讯作者：
Takayanagi H
影响因子：
30.8
作者：
通讯作者：
--
影响因子：
30.8
作者：
Kugathasan, Subra;Baldassano, Robert N.;Bradfield, Jonathan P.;Sleiman, Patrick M. A.;Imielinski, Marcin;Guthery, Stephen L.;Cucchiara, Salvatore;Kim, Cecilia E.;Frackelton, Edward C.;Annaiah, Kiran;Glessner, Joseph T.;Santa, Erin;Willson, Tara;Eckert, Andrew W.;Bonkowski, Erin;Shaner, Julie L.;Smith, Ryan M.;Otieno, F. George;Peterson, Nicholas;Abrams, Debra J.;Chiavacci, Rosetta M.;Grundmeier, Robert;Mamula, Petar;Tomer, Gitit;Piccoli, David A.;Monos, Dimitri S.;Annese, Vito;Denson, Lee A.;Grant, Struan F. A.;Hakonarson, Hakon
通讯作者：
Hakonarson, Hakon